Weight Loss & Metabolic

The Most Prescribed Drug in Human History. STEP Program: -14.9% Body Weight at 68 Weeks. SELECT Trial: 20% Reduction in Major Cardiovascular Events. Grade A Evidence Across the Broadest Human Trial Program among compounds in this reference set. The Weight Rebound Question: 2/3 of Weight Returns Within 1 Year of Stopping in Controlled Trials. The Compounded Semaglutide Regulatory Crisis. What the Real-World Data Actually Shows About Discontinuation.

Dual GLP-1/GIP agonist with A-grade evidence — the standard-of-care anchor for the modern incretin era.

The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.

Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.

Oral small-molecule pan-AMPK activator and mitochondrial uncoupler in active Phase 1b/2 clinical development. Formerly O-304, now ATX-304 under Amplifier Therapeutics / Cambrian Bio. Phase 2a human data show fasting glucose reduction in type 2 diabetes; obesity and cardiometabolic outcomes remain investigational.

The Mitochondrial Uncoupler That Doesn't Kill You. DNP Kills People in 2026. BAM15 Was Designed to Solve That. Fat Loss Without Hyperthermia. Without Reduced Food Intake. Without Lean Mass Loss. Without Toxicity Markers. In Mice. Nature Communications 2020. Zero Human Trials. The Most Mechanistically Elegant Fat Loss Compound in this reference — and the Most Preclinical.

Novo Nordisk's Long-Acting Amylin Analogue. The First New Mechanism in Obesity Pharmacology Since GLP-1. Phase 3 REDEFINE 1 (NEJM, June 2025): CagriSema = 22.7% Weight Loss — Among the Highest Ever Reported for Obesity Medication. Cagrilintide Monotherapy = 11.8% at 68 Weeks. Phase 3 Trials Completed. NDA Filing Expected Q1 2026. Not Yet Approved. Community Access Through Research Vendors.

GlaxoSmithKline Halted Their Own Drug in 2007 Because It Caused Cancer in Every Animal Species They Tested. The Community Is Still Using It. The Drug Worked. That Is the Entire Problem.

GH stack plus tesamorelin: a community combination built from GH-axis peptides with different regulatory identities, not a single FDA-approved product.

Eli Lilly's Selective Amylin Receptor Agonist. The Most Recent Lancet Publication in this reference (December 2025). Phase 2 Completed August 2025: 9.5-20.1% Weight Loss vs 0.4% Placebo at 48 Weeks. Phase 3 Just Started Enrollment (December 2025). The AMY1R-Selective Design: 12x More Selective for AMY1R vs CTR — Potentially Addressing the Two Biggest Limitations of Non-Selective Amylin Agonists (Nausea and Medullary Thyroid Carcinoma Risk). Lilly's Amylin Answer to Tirzepatide's GIP Addition.

The Compound Every Secretagogue in this reference Targets. 191 Amino Acids. FDA-Approved for GH Deficiency, HIV Wasting, Short Bowel Syndrome. July 2025: Skytrofa Once-Weekly Now Approved for Adults. The Pulsatile vs Continuous GH Exposure Distinction. IGF-1 as the Surrogate Marker. The Fake HGH Crisis. WADA S2 Absolute Ban. Why Secretagogues (Sermorelin, Ipamorelin, MK-677) Are Different. The Active Malignancy Hard Stop. The Cancer-IGF-1 Question That Never Goes Away.

Amino-acid-derived quaternary ammonium compound involved in mitochondrial fatty-acid transport. Commercial claims are often overstated, but specific forms have clinical evidence for neuropathy, peripheral artery disease, muscle recovery, male infertility, and post-MI cardiac outcomes.

Compounded MIC/B-12 lipotropic formulation that varies by pharmacy and is widely sold through weight-loss clinics. Evidence is strongest at the component level, especially inositol in PCOS/insulin resistance and injectable B12 for deficiency; weight-loss claims for the full blend remain weak.

⚠ NAMING COLLISION: 'Lipo-C' is used for TWO completely different products — this chapter covers the compounded MIC+L-Carnitine+B-vitamins lipotropic injection. Liposomal Vitamin C (a separate oral supplement also called 'Lipo-C') is covered in a separate chapter. Read Section 1 before proceeding. Lipo-B Extended: Adds L-Carnitine, Thiamine (B1), and Dexpanthenol (B5) to the Lipo-B MIC+B12 base. Zero RCTs for the combination. L-Carnitine Injectable Dose is 100-200x Below Oral Therapeutic Doses. Mechanistically Coherent. Clinically Unproven.

The World's First Approved Dual GCG/GLP-1 Receptor Agonist. NMPA-Approved in China June 2025 for Obesity. Second NMPA Approval September 2025 for T2D. Phase 3 T2D Data Published Back-to-Back in Nature December 2025. Originally Eli Lilly's LY3305677 — Licensed to Innovent Biologics for China Development. No FDA Submission as of Mid-2026. The Drug That Is Simultaneously Approved, Unavailable, and a Research Chemical Depending on Where You Are.

One Molecule That Tans Your Skin, Triggers Erections, Suppresses Appetite, and Elevates Blood Pressure — All Through Different Receptors on the Same Injection. The University of Arizona Drug That Spawned PT-141. Why the 'Barbie Drug' TikTok Trend Is the Most Dangerous Community Use Pattern in this reference. The Melanoma Question: Four Case Reports, Two Conflicting Reviews, and One Confound. Rhabdomyolysis at 12x the Starting Dose. What the Nasal Spray Market Actually Contains.

MIC injection tradition originates from lipotropic injection protocols developed in bariatric and weight loss medicine

The TAME Trial: The First FDA-Recognized Study to Use 'Aging' as a Drug Indication. The Bannister Study: Diabetics on Metformin Outlive Non-Diabetics. The 2024 Cell Primate Paper: 6.1-Year Brain Aging Regression. The Exercise Controversy: Metformin Blunts the Mitochondrial Benefits of Training. B12 Depletion: The Most Important Long-Term Safety Issue. Metformin vs Rapamycin: The Same mTOR Pathway, Different Entry Points. Who Benefits Most. Who Shouldn't Use It.

Mitochondrial-derived peptide studied for AMPK signaling, metabolic stress resilience, and exercise-mimetic pathways.

First Signaling Peptides Derived from the Mitochondrial Genome

The First True Oral GLP-1: Take It Anytime, With or Without Food, No Injection. ATTAIN-1 (NEJM 2025; n=3,127; 72 Weeks): -11.2% Body Weight at 36mg. Why Small Molecule Matters: The Chemistry That Makes This Pill Possible When No Peptide Could Be. Orforglipron vs Oral Semaglutide vs Injectable GLP-1s: The Efficacy-Accessibility Trade-Off. ATTAIN-MAINTAIN: It Maintains Weight Loss After Switching Off Wegovy and Zepbound. Why This Compound Changes Who Gets GLP-1 Therapy.

28.7% Weight Loss in Phase 3. The Most Effective Weight Loss Drug Ever Trialed. Not Approved. Not Available by Prescription. The Community Is Already Using It. And It Is Not the Same Drug as Tirzepatide.

Genuinely FDA-Approved for 18 Years. Withdrawn for Commercial Reasons, Not Safety. The Gateway Anti-Aging Peptide for a Decade of Compounding Medicine. Put on Category 2 in 2023. Apparently Returned to Category 1 Before the Broader 2026 Reclassification. The Cleanest Safety Profile of Any GH Secretagogue. The Somatostatin Feedback Ceiling That Makes It Physiologically Impossible to Overdose.

The Compound Designed for Patients Whose Brains Literally Cannot Signal 'Stop Eating.' The POMC/LEPR/PCSK1 Pathway Explained: Why These Patients Gain Weight from the Day They Are Born. 80% Achieved ≥10% Weight Loss in the POMC Trial. 51 kg Lost in a Single Patient in Phase II. The Off-Label Question: Does It Work When the Pathway Is Intact? Why 78% of Patients Develop Skin Hyperpigmentation — and Why That Is Not the Same Risk as Melanotan II. vs MT-II: Same Receptor Family, Opposite Selectivity Approach.

The Metabolically Active Member of a Six-Peptide Family From the Same Mitochondrial Gene as Humanin. A Receptor Has Been Found. An Obesity Protection Mechanism Has Been Identified. Lower Levels Are Associated With Prostate Cancer Risk. No Human Trial Has Been Run.

Synthetic small-molecule ERRα/β/γ agonist with large endurance gains in mice, zero human trials, and WADA prohibition ahead of human efficacy data.

The Glucagon Rehabilitation Story. Phase 2 MASH (NEJM July 2024): 62% MASH Resolution vs 14% Placebo. Phase 3 SYNCHRONIZE-1 (April 2026): -16.6% Weight Loss at 76 Weeks. FDA Breakthrough Therapy for MASH September 2024. LIVERAGE Phase 3 MASH Ongoing. Why Glucagon in Metabolic Disease? The GLP-1 + GCGR Advantage Over GLP-1 + GIPR for Liver Disease. The Most Important Obesity Drug for MASH Patients That Nobody in the Community Has Heard Of.

FDA-approved GHRH analog for HIV-associated lipodystrophy, used clinically to reduce visceral adipose tissue via pulsatile GH/IGF-1 signaling.

Oral small-molecule triple monoamine reuptake inhibitor originally developed for Alzheimer’s and Parkinson’s disease, with weight loss discovered as an incidental finding. Phase 2b data showed large weight-loss signal alongside the same heart-rate liability that limited earlier sympathomimetic obesity drugs.